Abiopharma

SCHRODINGER, INC. (SDGR)

Symbol	SDGR
Name	SCHRODINGER, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	1540 BROADWAY,24TH FLOOR, NEW YORK, New York, 10036, United States
Telephone	+1 212 295-5800
Fax	—
Email	—
Website	https://www.schrodinger.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001490978
Description	Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations. Additional info from NASDAQ: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

2026-07-01 19:19

📋 Aklian Mannix Vartan (Officer) plans to sell 1K shares of Schrodinger, Inc. (at $16.68 each, total $19K) Filed: Jul 01, 2026 | ID: 005022

2026-06-29 20:39

Director Friesner Richard 🟡 adjusted position in 0 shares of Schrodinger, Inc. (SDGR) Transaction Date: Jun 26, 2026 | Filing ID: 000004

2026-06-29 20:29

(99% Neutral) SCHRODINGER, INC. (SDGR) Announces Regulatory Update

2026-06-23 21:01

Director OBEROI ARUN 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000056

2026-06-23 20:38

Director Chodakewitz Jeffrey 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000003

2026-06-23 20:38

Director Friesner Richard 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000002

2026-06-23 20:37

Director GINSBERG GARY L 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000002

2026-06-23 20:33

Director Kapeller-Libermann Rosana 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000001

2026-06-23 20:32

Director Lynton Michael 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000001

2026-06-23 20:29

Director Sender Gary 🟢 acquired 21.5K shares (1 derivative) of Schrodinger, Inc. (SDGR) at $15.23 Transaction Date: Jun 22, 2026 | Filing ID: 000003

No clinical trials found for this company.

No clinical products found for this company.